2024年12月24日 · Complete information for DUSP22 gene (Protein Coding), Dual Specificity Phosphatase 22, including: function, proteins, disorders, pathways, orthologs, and expression.

2022年10月8日 · Dual specificity phosphatase 22 (DUSP22, also known as JKAP or JSP-1) expressed in numerous tissues plays essential biological functions in immune responses and tumor growth. However, the...

2024年6月14日 · Exogenous DUSP22 expression reduces the colony-forming capacity of lung cancer cells and inhibits xenograft tumor growth primarily by targeting EGFR and suppressing its activity through...

2017年7月27日 · In the present study, we evaluated the prognostic impact of DUSP22 and TP63 rearrangements in diagnostic tumor biopsy specimens from a population-based Danish cohort of 138 patients with nodal PTCLs.

2025年3月4日 · ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.

2024年1月15日 · DUSP22 is a dual-specificity phosphatase that inhibits T cell activation by inactivating the kinase Lck. Here we show that the E3 ubiquitin ligase UBR2 is a positive upstream regulator of Lck...

Herein, we aimed to unravel the molecular mechanisms governing AKT dephosphorylation, with a specific emphasis on dual-specificity phosphatases DUSP22. Our investigation sought to shed light on the potential of DUSP22 as a potential therapeutic …

2023年6月1日 · DUSP22 rearrangement (R) has been associated with a favorable outcome in systemic ALK-negative anaplastic large cell lymphoma (ALCL). However, a recent study found that patients with DUSP22-R ALK-negative ALCL have a …

DUSP22 belongs to a family of atypical small molecular mass dual-specificity phosphatases (DSPs) that dephosphorylate both tyrosine and serine/threonine residues. DUSP22 has multiple physiologic substrates and participates in various signaling cascades (summary by Li et al., 2010).

Dual specificity phosphatase 22 (DUSP22) is a gene that encodes a protein that functions in the activation of the JNK signaling pathway. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.